Author name: seo

The rise of GLP-1 peptide drugs like semaglutide and tirzepatide has pushed peptide manufacturing into overdrive. Every gram of these molecules is built one amide bond at a time, and none of those bonds form on their own. A carboxylic acid and an amine sitting next to each other at room temperature just form a […]

Antibody-drug conjugates get called biological missiles for a reason. The antibody finds the tumor cell, the payload kills it, and sitting between them is a small chemical structure that most people never think about until it fails. That structure is the ADC linker, and it decides whether the drug works safely or causes serious toxicity.

Drug development costs keep climbing, and fewer companies want to build their own manufacturing plants from scratch. Outsourcing has become the default path, not the exception. But once you start talking to vendors, two acronyms show up everywhere: CMO and CDMO. They sound similar, and some sales reps use them interchangeably, but picking the wrong

Two enantiomers of the same molecule share almost every physical property. They boil at the same temperature. They melt at the same point. They dissolve the same way in the same solvent. A standard distillation column cannot tell them apart, and neither can ordinary chromatography. So how does the pharmaceutical industry actually separate one mirror-image

In 2018, regulators pulled valsartan tablets off shelves worldwide after finding trace amounts of a chemical called NDMA inside the active ingredient. Ranitidine and metformin followed a similar path over the next two years. The common thread was a class of compounds known as nitrosamines, and the fallout changed how the entire industry looks at

Most drug molecules on the market today carry at least one stereocenter, and the atom that becomes that stereocenter usually starts out flat, symmetric, and achiral. Chemists call this starting point prochiral. It’s not a chiral molecule yet, but it’s one reaction away from becoming one. This idea sits at the center of asymmetric synthesis.

API manufacturers spend years developing a synthesis route. That route contains process steps, impurity controls, and material specifications that competitors would love to copy. At the same time, the FDA needs to see all of that detail before it lets a drug reach patients. These two needs pull in opposite directions, and the drug master

You spend weeks purifying a compound to 99% ee, and if storage conditions are wrong, that single enantiomer slides back toward a 50:50 mixture within days. That process is racemization, the conversion of an optically active compound into a racemic mixture, along with the loss of optical activity. The molecule doesn’t disappear and no bonds

Two molecules can share the exact same chemical formula and the exact same atom-to-atom connections, yet behave completely differently in the body. The only difference between them is a mirror-image arrangement in 3D space. This is optical isomerism, and it’s one of the more surprising ideas in organic chemistry once you see it in action.

Peptide drugs are having a moment. GLP-1 medicines like semaglutide and tirzepatide have turned peptide manufacturing into one of the busiest corners of the pharmaceutical industry. Behind almost all of that production sits one core method: solid phase peptide synthesis, or SPPS. The technique was developed by Robert Bruce Merrifield in the 1960s, work that

In chiral chemistry, making a molecule with the right handedness is only half the job. What actually matters is how much of the wrong handed version is mixed in. Enantiomeric excess, usually written as ee, is the number chemists use to describe that purity. It tells you how far a mixture sits from being 50:50

What Is a Stereocenter A stereocenter (also called a stereogenic center) is any atom in a molecule where swapping two attached groups produces a different stereoisomer. That’s the whole definition. It doesn’t say anything about mirror images or optical activity — it just says the swap changes the molecule’s 3D arrangement. This is a broad